Belite Bio (BLTE) Change in Accured Expenses (2024 - 2025)
Belite Bio's (BLTE) quarterly Change in Accured Expenses came in at $1.8 million in Q4 2025, down 36.71% year-on-year from $2.9 million in Q4 2024, and down 36.71% quarter-over-quarter from $2.9 million in Q4 2024.
Belite Bio (BLTE) Change in Accured Expenses (2024 - 2025) Analysis & Trends
Belite Bio's Change in Accured Expenses history runs 2 years deep, the most recent figure standing at $1.8 million for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -16.74 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -176.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.84 Mn |
| Dec 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 2.91 Mn |
| Dec 31, 2024 | 2.91 Mn |